# NIH Awards Tempo Therapeutics SBIR Grant

Tempo Therapeutics, Inc., a regenerative medicine company based in San Diego, California, has been awarded a **$2.25 million Small Business Innovation Research (SBIR) grant** by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to support a two-year randomized clinical study of its Microporous Annealed Particle (MAP) Wound Matrix technology. This study focuses on improving complex wound healing and accelerating graft readiness following non-melanoma skin cancer surgeries involving exposed bone. The grant, awarded on September 23, 2026, advances Tempo's clinical validation and regulatory efforts without equity dilution, highlighting a significant federal investment in innovative biomaterials and regenerative medicine.

- **Why this matters:** This funding opportunity signals growing federal support for advanced wound care technologies, creating potential procurement and partnership opportunities for contractors specializing in clinical research, biomaterials, and medical device development.
- The clinical study aims to demonstrate MAP's ability to accelerate healthy tissue regeneration while minimizing inflammatory responses, which could transform treatment protocols for complex wounds.
- Procurement professionals should note the involvement of NIH/NCI as a key funding agency and the potential for follow-on contracts or collaborations in regenerative medicine.
- Companies in healthcare technology and government contracting may benefit from aligning with Tempo Therapeutics' development timeline and exploring complementary service offerings in clinical trial support and biomaterial manufacturing.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Grants & Funding
**Published:** September 25, 2026

### Government Entities
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)

### Vendors
- Tempo Therapeutics, Inc. (awardee)

### Key Quotes
> This award brings Tempo closer to an important value-enhancing milestone: demonstrating that MAP can provide a fundamentally different approach to wound management by accelerating the formation of healthy tissue while minimizing the inflammatory foreign-body response.
> — Steven Sands, Chairman

### Sources
- [Tempo Therapeutics Awarded $2.25 Million NIH SBIR Grant to Advance MAP™ Technology for Complex Wound Healing](https://www.prnewswire.com/news-releases/tempo-therapeutics-awarded-2-25-million-nih-sbir-grant-to-advance-map-technology-for-complex-wound-healing-302886973.html) - PR Newswire
- [Tempo Therapeutics lands $2.3M SBIR grant for wound-healing tech | Dealroom.co](https://app.dealroom.co/news/note/tempo-therapeutics-lands-2-3m-sbir-grant-for-wound-healing-tech) - Dealroom
- [Tempo Therapeutics Awarded $2.25 Million NIH SBIR Grant to Advance MAP™ Technology for Complex Wound Healing - BioSpace](https://www.biospace.com/press-releases/tempo-therapeutics-awarded-2-25-million-nih-sbir-grant-to-advance-map-technology-for-complex-wound-healing) - BioSpace